Floris S. Verheij

Floris S. Verheij

Auto-generated profile, based on publicly available information

Floris S. Verheij

Department of Surgery, Colorectal Service, Memorial Sloan Kettering Cancer Center, New York, NY

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JGJulio Garcia-Aguilar
Julio Garcia-Aguilar
SPSujata Patil
Sujata Patil
MGMarc J. Gollub
Marc J. Gollub
JKJin K. Kim
Jin K. Kim
Jonathan Benjamin YuvalJonathan Benjamin Yuval
Jonathan Benjamin Yuval
LSLeonard B. Saltz
Leonard B. Saltz
PURPOSE: Prospective data on the efficacy of a watch-and-wait strategy to achieve organ preservation in patients with locally advanced rectal cancer treated with total neoadjuvant therapy are limited. METHODS: In this prospective, randomized phase II trial, we assessed the outcomes of 324 patients with stage II or III rectal adenocarcinoma treated with induction chemotherapy followed by chemoradiotherapy (INCT-CRT) or chemoradiotherapy followed by consolidation chemotherapy (CRT-CNCT) and either total mesorectal excision (TME) or watch-and-wait on the basis of tumor response. Patients in both groups received 4 months of infusional fluorouracil-leucovorin-oxaliplatin or capecitabine-oxaliplatin and 5,000 to 5,600 cGy of radiation combined with either continuous infusion fluorouracil or capecitabine during radiotherapy. The trial was designed as two stand-alone studies with disease-free survival (DFS) as the primary end point for both groups, with a comparison to a null hypothesis on the basis of historical data. The secondary end point was TME-free survival. RESULTS: Median follow-up was 3 years. Three-year DFS was 76% (95% CI, 69 to 84) for the INCT-CRT group and 76% (95% CI, 69 to 83) for the CRT-CNCT group, in line with the 3-year DFS rate (75%) observed historically. Three-year TME-free survival was 41% (95% CI, 33 to 50) in the INCT-CRT group and 53% (95% CI, 45 to 62) in the CRT-CNCT group. No differences were found between groups in local recurrence-free survival, distant metastasis-free survival, or overall survival. Patients who underwent TME after restaging and patients who underwent TME after regrowth had similar DFS rates. CONCLUSION: Organ preservation is achievable in half of the patients with rectal cancer treated with total neoadjuvant therapy, without an apparent detriment in survival, compared with historical controls treated with chemoradiotherapy, TME, and postoperative chemotherapy.

10 February 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FVFloris S. Verheij
Floris S. Verheij
DODana M. Omer
Dana M. Omer
HWHannah Williams
Hannah Williams
SLSabrina T. Lin
Sabrina T. Lin
LQLi-Xuan Qin
Li-Xuan Qin
JGJulio Garcia-Aguilar
Julio Garcia-Aguilar
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. To assess long-term risk of local tumor regrowth, we report updated organ preservation rate and oncologic outcomes of the OPRA trial (ClinicalTrials.gov identifier: NCT02008656 ). Patients with stage II/III rectal cancer were randomly assigned to receive induction chemotherapy followed by chemoradiation (INCT-CRT) or chemoradiation followed by consolidation chemotherapy (CRT-CNCT). Patients who achieved a complete or near-complete response after finishing treatment were offered watch-and-wait (WW). Total mesorectal excision (TME) was recommended for those who achieved an incomplete response. The primary end point was disease-free survival (DFS). The secondary end point was TME-free survival. In total, 324 patients were randomly assigned (INCT-CRT, n = 158; CRT-CNCT, n = 166). Median follow-up was 5.1 years. The 5-year DFS rates were 71% (95% CI, 64 to 79) and 69% (95% CI, 62 to 77) for INCT-CRT and CRT-CNCT, respectively ( P = .68). TME-free survival was 39% (95% CI, 32 to 48) in the INCT-CRT group and 54% (95% CI, 46 to 62) in the CRT-CNCT group ( P = .012). Of 81 patients with regrowth, 94% occurred within 2 years and 99% occurred within 3 years. DFS was similar for patients who underwent TME after restaging (64% [95% CI, 53 to 78]) and patients in WW who underwent TME after regrowth (64% [95% CI, 53 to 78]; P = .94). Updated analysis continues to show long-term organ preservation in half of the patients with rectal cancer treated with total neoadjuvant therapy. In patients who enter WW, most cases of tumor regrowth occur in the first 2 years.

1 September 2024 in Radiology
Verified
Journal Article
Closed access
HWHannah Williams
Hannah Williams
DODana M. Omer
Dana M. Omer
HTHannah M. Thompson
Hannah M. Thompson
SLSabrina T. Lin
Sabrina T. Lin
FVFloris S. Verheij
Floris S. Verheij
LSLeonard B. Saltz
Leonard B. Saltz
Restaging MRI can stratify patients treated with total neoadjuvant therapy into clinical response categories predictive of organ preservation, local regrowth, and survival.

17 June 2022 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
Jonathan Benjamin YuvalJonathan Benjamin Yuval
Jonathan Benjamin Yuval
JLJasme Lee
Jasme Lee
FWFan Wu
Fan Wu
HTHannah M. Thompson
Hannah M. Thompson
FVFloris S. Verheij
Floris S. Verheij
JMJoshua S. Mincer
Joshua S. Mincer

4 August 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
FVFloris S. Verheij
Floris S. Verheij
DODana M. Omer
Dana M. Omer
SLSabrina T. Lin
Sabrina T. Lin
JYJonathan B. Yuval
Jonathan B. Yuval
HTHannah M. Thompson
Hannah M. Thompson
JGJulio Garcia-Aguilar
Julio Garcia-Aguilar

9 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DODana M Omer
Dana M Omer
HTHannah M. Thompson
Hannah M. Thompson
FVFloris S. Verheij
Floris S. Verheij
Jonathan Benjamin YuvalJonathan Benjamin Yuval
Jonathan Benjamin Yuval
RRRoni Rosen
Roni Rosen
FSFrancisco Sanchez-Vega
Francisco Sanchez-Vega
A small proportion of rectal adenocarcinomas develop in patients many years after the treatment of a previous cancer using pelvic radiation, and the incidence of these rectal cancers depends on the length of follow-up from the end of radiotherapy. The risk of radiation-associated rectal cancer (RARC) is higher in patients treated with prostate external beam radiotherapy than it is in patients treated with brachytherapy. The molecular features of RARC have not been fully investigated, and survival is lower compared to non-irradiated rectal cancer patients. Ultimately, it is unclear whether the worse outcomes are related to differences in patient characteristics, treatment-related factors, or tumor biology. Radiation is widely used in the management of rectal adenocarcinoma; however, pelvic re-irradiation of RARC is challenging and carries a higher risk of treatment complications. Although RARC can develop in patients treated for a variety of malignancies, it is most common in patients treated for prostate cancer. This study will review the incidence, molecular characteristics, clinical course, and treatment outcomes of rectal adenocarcinoma in patients previously treated with radiation for prostate cancer. For clarity, we will distinguish between rectal cancer not associated with prostate cancer (RCNAPC), rectal cancer in non-irradiated prostate cancer patients (RCNRPC), and rectal cancer in irradiated prostate cancer patients (RCRPC). RARC represents a unique but understudied subset of rectal cancer, and thus requires a more comprehensive investigation in order to improve its treatment and prognosis.